DR.AGARWALS EYE HOSPITAL LTD.-$

Dr Agarwals Eye Hospital Ltd has announced its 32nd Annual General Meeting (AGM) will be held on September 09, 2026, at 10:30 AM IST via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The agenda includes adopting the audited financial statements for FY2025-26, declaring a final dividend of INR 4.00 per equity share, re-appointing Dr. Adil Agarwal as a director, ratifying remuneration for the cost auditor, and approving revised remuneration for the Chairman cum Managing Director, Dr. Amar Agarwal. The record date for the dividend payment is September 02, 2026, with payment expected by October 08, 2026.

Dr Agarwals Eye Hospital Ltd has announced the record date for the payment of its final dividend for the financial year 2025-26. The dividend of ₹4.00 per equity share (40%) is subject to member approval at the upcoming 32nd Annual General Meeting (AGM) scheduled for September 09, 2026. The record date for determining eligible shareholders is set as September 02, 2026. The dividend payment is expected to be made on or before October 08, 2026. The AGM will also cover the adoption of financial statements, director re-appointment, and ratification of cost auditor remuneration.

Dr Agarwal's Eye Hospital Ltd has submitted its Annual Report for the financial year 2025-26, along with the notice for its 32nd Annual General Meeting (AGM). The AGM is scheduled for September 09, 2026, at 10:30 AM IST, to be held via Video Conferencing. The company is facilitating e-voting for the AGM through CDSL's platform, in compliance with SEBI Listing Regulations and the Companies Act. Electronic dispatch of the annual reports to members commenced on August 14, 2026. The report includes financial highlights, directors' report, management discussion, corporate governance, and independent auditor's report.

Invesco Mutual Fund, through various schemes, has increased its aggregate holding in Dr Agarwals Healthcare Limited (the Company) to 5.2125% of the paid-up share capital. The acquisition involved 69,38,186 equity shares, bringing the total holding to 1,65,25,130 shares as of August 12, 2026. This disclosure is made in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The total equity share capital of the company remains Rs. 31,70,26,183/-.

Dr Agarwals Eye Hospital Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the results and the Limited Review Report from the Statutory Auditors. The company also re-appointed M/s. B'Y & Associates as Cost Auditors for FY 2026-27. The financial results will be published in newspapers and made available on the company's website.

Dr Agarwals Eye Hospital Ltd announced the reappointment of M/s. B Y & Associates as Cost Auditors for the financial year 2026-27. This decision was approved by the Board of Directors during their meeting held on August 03, 2026. The board also considered and approved the unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Report from the statutory auditors. These results will be published in newspapers and made available on the company's website. The meeting commenced at 3:00 PM IST and concluded at 3:45 PM IST.

Dr. Agarwal's Eye Hospital's standalone revenue rose 22.3% YoY to ₹142.97 Cr (₹116.92 Cr) and 19.1% QoQ (₹120.01 Cr), with PAT up 35.5% YoY to ₹23.38 Cr (₹17.26 Cr) and 44.0% QoQ (₹16.24 Cr). Basic EPS (not annualised) came in at ₹48.38 versus ₹36.72 a year ago. There is no street consensus or management guidance on record for this specific quarter — our records carry no prior guidance, and a web search turned up only a broad FY25-27 estimate (analysts had pencilled ~20%/21%/39% revenue/EBITDA/PAT CAGR), not a quarter-specific number, so vsStreet and vsGuidance are marked unknown rather than inferred. The margin picture is split by line. Net profit margin (on total income) expanded to 16.1% from 14.7% YoY (+147 bps) and from 13.4% QoQ (+277 bps), but this improvement sits below the operating line: operating margin actually compressed to 30.3% from 31.8% a year ago (-150 bps) as "other expenses" jumped 39.4% YoY to ₹22.42 Cr, outpacing the 22.3% revenue growth, while consultancy charges for doctors (+27.8%) and employee costs (+23.9%) also ran ahead of the topline. What pulled PAT growth above operating-profit growth was finance costs falling 33.4% YoY to ₹2.77 Cr from ₹4.16 Cr — the single largest swing factor in the bridge from PBT (+33.5% YoY) to PAT (+35.5% YoY). Two corporate-action threads ran alongside the print. The proposed amalgamation with holding company Dr. Agarwal's Health Care Ltd ccleared equity, secured-creditor and unsecured-creditor votes on July 2, 2026, and now awaits final NCLT sanction — a structural change to track but with no P&L impact yet. Separately, of the ₹70 Cr raised via the September 2025 preferential allotment (1,32,827 shares at ₹5,270 each), only ₹28.20 Cr has been utilised as per the stated objects; the remaining ₹41.80 Cr sits in debt mutual funds, a plausible funding source for further deleveraging that could extend the finance-cost tailwind seen this quarter. No separate management press release accompanied this filing, so the framing here is drawn directly from the results statement and its notes rather than management commentary.

Dr Agarwals Eye Hospital Ltd has announced that its Board of Directors will convene on August 3, 2026. The primary agenda for this meeting is to consider and approve the unaudited financial results for the quarter ending June 30, 2026. In line with SEBI regulations, the company has also informed that the trading window will remain closed until 48 hours after the announcement of these financial results. Further details are available on the company's website.

Dr Agarwal's Eye Hospital Limited announced that the Hon'ble National Company Law Tribunal (NCLT) convened meeting of its Secured Creditors, held on July 02, 2026, approved the proposed Scheme of Amalgamation between Dr. Agarwal's Eye Hospital Limited and Dr. Agarwal's Health Care Limited. The approval was secured through remote e-voting, e-voting at the venue, and voting via polls. The resolutions were deemed passed as of July 02, 2026, following the scrutiny by Shri Sriram Ananth, as appointed by the NCLT.

Dr. Agarwal's Eye Hospital Limited held an NCLT-convened meeting of its unsecured creditors on July 2, 2026, to approve a Scheme of Amalgamation with Dr. Agarwal's Health Care Limited. The meeting, chaired by Shri Kanwal Jeet Arora, saw the requisite quorum of 31 unsecured creditors present. Resolutions concerning the amalgamation scheme were duly transacted and approved by the unsecured creditors, as per the notice and explanatory statement provided. The company has also made this information available on its website.